Predictors of Respiratory Failure in SARS-Cov-2 Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04316949|
Recruitment Status : Unknown
Verified April 2020 by Michele Bartoletti, University of Bologna.
Recruitment status was: Recruiting
First Posted : March 20, 2020
Last Update Posted : April 7, 2020
The emergence of SARS-CoV-2 is currently engaging and consuming most of resources of efficient healthcare systems in Europe, and several hospitals are currently experiencing a shortage of ICU beds for critically-ill patients with SARS-CoV-2 pneumonia.
A risk stratification based on clinical, radiological and laboratory parameters seems necessary in order to better identify those patients who may need ICU admission and/or those who may benefit from a prompt antiviral therapy
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||350 participants|
|Official Title:||Predictors of Respiratory Failure Requiring ICU Admission Among Hospitalized Patients With SARS-Cov-2 Infection|
|Actual Study Start Date :||March 20, 2020|
|Estimated Primary Completion Date :||April 30, 2020|
|Estimated Study Completion Date :||May 31, 2020|
Derivation cohort: Italian retrospective cohort of all consecutive hospitalized patients with SARS-CoV-2 pneumonia in the participating centers, from February 20 to March 19 2020.
Validation cohort: European and non-European retrospective cohort of all consecutive hospitalized patients with SARS-CoV-2 pneumonia in the participating centers, from March 19 to April 18 2020.
- Respiratory failure [ Time Frame: 14 days ]Composite of ICU admission or SpO2<92% with 100% FiO2 of oxygen treatment (reservoir mask or CPAP or NIV), respiratory rate >30 bpm, respiratory distress
- Occurence of bacterial superinfection [ Time Frame: 14 days ]Incidence of bacterial superinfection among ventilated patients with SARS-CoV-2 pneumonia
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04316949
|University of Bologna - Department of Medical and Surgical Sciences||Recruiting|
|Bologna, Italy, 40138|
|Contact: Pierluigi Viale, MD + 39 051 214 3018 firstname.lastname@example.org|